Hsbc Holdings Plc Has Lowered Its Vertex Pharmaceuticals (Call) (VRTX) Position; Last Week Intercontinental Exchange, Inc. (ICE) Analysts

January 14, 2018 - By Hazel Jackson

Among 16 analysts covering Intercontinental Exchange (NYSE:ICE), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Intercontinental Exchange had 60 analyst reports since August 6, 2015 according to SRatingsIntel. As per Thursday, July 13, the company rating was upgraded by RBC Capital Markets. Wood maintained Intercontinental Exchange, Inc. (NYSE:ICE) on Friday, March 24 with “Buy” rating. Sterne Agee CRT initiated Intercontinental Exchange, Inc. (NYSE:ICE) on Friday, May 20 with “Buy” rating. The stock of Intercontinental Exchange, Inc. (NYSE:ICE) earned “Neutral” rating by Citigroup on Friday, November 3. On Tuesday, May 10 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. Citigroup maintained Intercontinental Exchange, Inc. (NYSE:ICE) on Thursday, October 19 with “Neutral” rating. The firm has “Overweight” rating given on Thursday, August 4 by Barclays Capital. The stock of Intercontinental Exchange, Inc. (NYSE:ICE) has “Buy” rating given on Thursday, August 4 by Deutsche Bank. Keefe Bruyette & Woods maintained Intercontinental Exchange, Inc. (NYSE:ICE) on Friday, October 6 with “Buy” rating. The firm has “Buy” rating given on Wednesday, October 11 by Jefferies. See Intercontinental Exchange, Inc. (NYSE:ICE) latest ratings:

21/12/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $81.5 Maintain
12/12/2017 Broker: Raymond James Rating: Buy
03/11/2017 Broker: Citigroup Rating: Neutral Old Target: $75 New Target: $77 Maintain
03/11/2017 Broker: UBS Rating: Buy Old Target: $73 New Target: $80 Maintain
02/11/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $74.0 Maintain
19/10/2017 Broker: Citigroup Rating: Neutral Old Target: $67 New Target: $75 Maintain
16/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $76.0 Maintain
11/10/2017 Broker: Jefferies Rating: Buy New Target: $73.0 Maintain
10/10/2017 Broker: Barclays Capital Rating: Overweight Old Target: $72 New Target: $78 Maintain
06/10/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $70.0 Maintain

Hsbc Holdings Plc decreased Vertex Pharmaceuticals Inc (Call) (VRTX) stake by 93.98% reported in 2017Q3 SEC filing. Hsbc Holdings Plc sold 240,359 shares as Vertex Pharmaceuticals Inc (Call) (VRTX)’s stock rose 33.61%. The Hsbc Holdings Plc holds 15,400 shares with $2.34 million value, down from 255,759 last quarter. Vertex Pharmaceuticals Inc (Call) now has $39.94B valuation. The stock decreased 0.30% or $0.47 during the last trading session, reaching $157.93. About 1.56M shares traded or 1.23% up from the average. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since January 14, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Investors sentiment increased to 1.62 in 2017 Q3. Its up 0.11, from 1.51 in 2017Q2. It improved, as 32 investors sold VRTX shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. Redmile Group Incorporated Ltd Liability Corporation has invested 1.42% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Alpine Glob Mngmt Ltd Com reported 1,835 shares. Paloma Ptnrs holds 0.02% or 11,123 shares in its portfolio. Saratoga Research & Inv Management owns 15 shares. Principal Financial Gp Inc holds 371,804 shares. Hightower Advsr Ltd Liability Company reported 15,987 shares. Private Advisor Gp Limited Liability Corporation invested 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Security Natl Trust Company reported 185 shares. Swiss National Bank owns 0.16% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 918,209 shares. Rock Springs Mngmt Lp accumulated 151,500 shares. Robeco Institutional Asset Mgmt Bv owns 15,672 shares. Btg Pactual Global Asset Limited invested in 4,389 shares. Northeast Financial Consultants holds 1.34% or 23,971 shares in its portfolio. Suntrust Banks has 26,937 shares for 0.02% of their portfolio. Sumitomo Mitsui Asset Management has invested 0.04% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Hsbc Holdings Plc increased Restaurant Brands Intl Inc stake by 18,031 shares to 56,474 valued at $3.61 million in 2017Q3. It also upped Cenovus Energy Inc (NYSE:CVE) stake by 829,592 shares and now owns 1.07 million shares. Waters Corp (NYSE:WAT) was raised too.

Since July 31, 2017, it had 0 buys, and 23 selling transactions for $64.38 million activity. Parini Michael sold 2,330 shares worth $362,828. Shares for $131,571 were sold by Silva Paul M on Monday, July 31. On Monday, July 31 the insider LEIDEN JEFFREY M sold $1.69 million. SMITH IAN F sold $324,865 worth of stock. 40,000 shares were sold by Sachdev Amit, worth $5.80M on Tuesday, October 31. $1.68 million worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by Bhatia Sangeeta N.. The insider Chodakewitz Jeffrey sold 3,437 shares worth $521,198.

Among 28 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 24 have Buy rating, 0 Sell and 4 Hold. Therefore 86% are positive. Vertex Pharmaceuticals had 81 analyst reports since July 31, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, September 16 by Nomura. The firm earned “Buy” rating on Thursday, July 27 by Oppenheimer. On Tuesday, September 1 the stock rating was upgraded by Vetr to “Buy”. The firm earned “Buy” rating on Thursday, October 26 by Needham. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Buy” rating given on Thursday, October 26 by Piper Jaffray. The stock has “Outperform” rating by Credit Suisse on Wednesday, January 20. The stock has “Outperform” rating by Leerink Swann on Friday, February 5. Jefferies maintained it with “Buy” rating and $105 target in Wednesday, October 5 report. Maxim Group maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Wednesday, July 19. Maxim Group has “Buy” rating and $19500 target. On Wednesday, March 29 the stock rating was upgraded by BMO Capital Markets to “Outperform”.

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on January, 24. They expect $0.28 EPS, up 115.38% or $0.15 from last year’s $0.13 per share. VRTX’s profit will be $70.81 million for 141.01 P/E if the $0.28 EPS becomes a reality. After $0.24 actual EPS reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts 16.67% EPS growth.

Intercontinental Exchange, Inc. operates regulated exchanges, clearing houses, and listings venues for financial and commodity markets in the United States, the United Kingdom, Continental Europe, Israel, Canada, and Singapore. The company has market cap of $43.75 billion. It operates in two divisions, Trading and Clearing, and Data and Listings. It has a 27.2 P/E ratio. The firm operates marketplaces for trading and clearing an array of derivatives and securities contracts across various asset classes, including energy and agricultural commodities, interest rates, equities, equity and credit derivatives, exchange traded funds, bonds, and currencies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>